HOME Research Insight Acquisitions and new Product Launches are the key Strategies Adopted by Major Players in the Biosurgery Market



Acquisitions and new Product Launches are the key Strategies Adopted by Major Players in the Biosurgery Market


The biosurgery market is characterized by the presence of large as well as small players operating at global and regional levels. Most of the key players in this market are based in developed countries across North America and Europe. Some of the leading players in this market include Baxter International Inc. (U.S.), C.R. Bard, Inc. (U.S.), Johnson & Johnson (U.S.), Covidien plc. (Ireland), and Sanofi Group (France).

Johnson & Johnson (U.S.) led the sealants and hemostatic agents market in 2015. This is majorly attributed to its strong product portfolio for this market. The company also has a wide global presence across North America, Europe, the Middle East and Africa, and Asia-Pacific, which has enabled it in serving a large customer base. In order to gain a competitive edge in this market, the company focuses on strategies such as new product launches and FDA approvals for additional indications of its products. For instance, in April 2015, Ethicon, LLC obtained U.S.FDA approval for EVARREST Fibrin Sealant Patch for an additional indication. The product which was used before for stopping problematic bleeding in surgeries can now be used as an adjunct to hemostasis for controlling bleeding during adult liver surgery. The expansion of indication for the product enabled the company in expanding its product offerings for different indications, and gaining greater penetrance in the biosurgery market.

Baxter Internal Inc. (U.S.) was the second-leading company in the global sealants and hemostatic agents market in 2015. The company has a strong presence across North America, Europe, the Middle East, Africa, and Asia-Pacific. The company’s strong manufacturing and distribution network across the globe has enabled it in establishing a strong foothold in the sealants and hemostatic agents market. Some of its prominent products for this market include FLOSEAL, TISSEEL, COSEAL, and TachoSil. The company further focuses on strategies such as collaborations and new product launches to sustain and grow in this market. For instance, in March 2015, the company entered into public-private collaboration with Changi General Hospital (Singapore). The development enabled the company in serving a more diverse base of customers and also in meeting the increasing demand of biosurgery products in the country.

Acquisitions and new product launches were the key strategies adopted by major players in the biosurgery marker from 2011 to 2016. Acquisitions and new product launches have enabled companies in increasing their customer base, meeting the growing demands of the emerging markets better, and in greater market penetration, ensuring long-term revenue generation.

Related Reports:

Biosurgery Market by Product (Fibrin & Collagen Sealant, Hemostats, Adhesion Barriers, Biological Meshs, Soft Tissue Attachments, Stapler, Bone Graft Substitues) Application (Orthopedic, Gynecology, Cardiovascular, Reconstructive) - Forecast to 2021

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports